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ABSTRACT 
Targeted drug delivery with nano-technology has been researched and identified as being efficient across many treatment 
conditions. This review assesses some of the existing research work and evidence practice in using nano-technology based drug 
carriers. 
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Introduction 
Targeted drug delivery or smart delivery is treatment 
methods that are used for the purpose of increasing 
medicine delivery and treatment efficacy1-3. Passive and 
active drug delivery methods are used with drug delivery 
vehicles that are even capable of crossing the blood-brain 
barrier4-8. This paper reviews the different Nano-
technology based drug carrier or drug delivery systems 
that have been implemented and tested in contemporary 
practices. The pros and differentiated aspects of such 
delivery systems as compared to others are discussed.  
Nano-technology forms of drug delivery 
Nano-technology based forms of drug delivery are one of 
the most popular methods of drug delivery. Nanoparticles 
are smaller in size and this allows for better delivery of 
drugs that do not dissolve in water and thus can complete 
the first pass through liver metabolism9-13. Since 
nanotechnology forms of drug delivery ensure that the 
drug is circulated in the body for a longer time, it means 
that the drug is functional for more time. Plasma levels are 
therefore less-fluctuating and more stable. Nano-
technology form of methods is useful against drug 
resistance effects. Nano-delivery methods can even cross 
the blood-brain barrier with least cytotoxicity14-17. These 
drug delivery methods are further extended as observed in 
the case of Yang et al.’s research work where gene delivery 
to cancer cells is facilitated. The delivery of nanoparticles 
through the blood-brain barriers as presented in Kang et 
al.,10 research is presented below.  
Yung et al., research focused on the efficient delivery of the 
AM-21 also called the microRNA-21 which is used in 
human cancer treatment. The authors propose the use of 
lipid nanoparticle formulations called the QTsome18-23. 
Nano-technology form of drug delivery was considered 
more effective in this situation. AM-21 is an effective 
therapeutic agent, but then after its release into the 
bloodstream, AM 21 is also cleared in a very fast manner 
from the bloodstream. Additionally, the medicine is not 
capable of penetrating the cellular membrane and hence 
does not deliver medicine to targeted sites efficiently. In 
the past, a chemical modification of the lipid nanoparticle 
backbone has been considered necessary24-27. The use of 
Nano-carriers in such situations showed enhanced 
therapeutic effects and reduced the cytotoxicity in normal 
cells. Off-target cytotoxicity was reduced to a great extent 
because of active targeting. Use of combination and Nano 
delivery methods reduces tumor growth more than others 
as highlighted below. 
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Figure 1: Nanoparticles and the BBB, (Kang et al.,) 
 
 
Figure 2: In-vivo results (Yung et al.,) 
The use of the QTsome as a novel nanoparticle formulation 
ensures that a more responsive profile is developed for 
medicine delivery28-30. Nanoparticle-based platforms for 
delivery are an enhanced system on account of its low 
molecular weight. The small size and high drug loading 
capacity of QTsome nanoparticle lend to better long-term 
stability.  
Targeted delivery 
Targeted delivery helps deliver the needed medicines to 
the sites of action. Camptothecin acts as a DNA 
topoisomerase 1 inhibitor. It is used as an anti-tumor 
agent. Replication of cancer DNA is terminated with the 
Camptothecin. Although exhibiting cytotoxicity against 
tumor cells, the E-lactone ring in the drug Camptothecin is 
unstable. As a result of its instability, inactive carboxylates 
are formed. Moreover, the drug has poor aqueous 
solubility31-34. Issues in biodistribution exist as well. In this 
context, targeted delivery systems such as the nano-
technology systems by property of selective deliverance 
will send the drugs directly into the tumor cell, instead of 
distributing it across normal tissues. Permeability and 
retention effects cause the delivery of nanoparticles across 
blood vessels as well. Compared to the traditional delivery 
modes, the medicine is retained for a much longer time.  
The work of Kang et al. on the delivery of nanoparticles in 
the case of brain tumor highlights how chemotherapy 
results in drug resistance issues and issues of cytotoxicity 
in off-target regions for brain tumors like the glioblastoma. 
Brain tumors cannot be detected at an early stage, and 
when detected, the usual course of treatment is surgery 
followed by chemotherapy or radiation. Chemotherapeutic 
drugs usually end up causing high levels of off-target 
cytotoxicity, and over time, patients could end up 
becoming resistance to some chemotherapeutic drugs as 
well. This drug resistance questions the efficacy of the 
treatment program for the patient. The efficacy of 
treatment becomes questionable. The chemotherapeutic 
drugs fail to cross through the blood-brain barrier (BBB) 
and the insufficient concentrations will not be enough to 
restrict the progressive growth of tumors in tumor sites 
even after debulking surgeries35-39. In this context, the 
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nanotechnology form of drug delivery crosses the barrier 
and delivers medicine at the tumor site. It is used in 
antipsychotic drug delivery. Psychosis is a severe mental 
health problem involving delusions, catatonia and more. 
Antipsychotics that are used for their treatment have many 
side effects. Sun et al. argue for the use of nanoparticles in 
antipsychotics administration. Brain targeting drugs help 
create slow release profiles of drugs that are far more 
aqueous soluble and efficient than other delivery forms. 
Nanotechnology can be used for the early detection of the 
tumor in some situations and its value is extended beyond 
just a carrier as observed in current research works. For 
example, consider the research work of Yang et al. where 
nanotechnology is applied to use nanoscaled exosome 
mimics NM. Exosomes are the smallest of the extracellular 
vehicles and contain genetic information for intercellular 
communication. The rapid abnormal proliferation of cells 
as in the case of cancer can be handled by communication 
of genetic and proteomic information through the nano-
technology applied exosome mimics. Both in-vitro and in-
vivo analysis holds many benefits10.  
Conclusion 
Targeted delivery methods ensure that drugs are delivered 
to the required site of action in an efficient manner. The 
work reviewed the Nano-technology drug delivery systems 
such as AM-21, Camptothecin, chemotherapeutic drugs for 
the brain tumor and antipsychotic drugs for psychosis. The 
targeted delivery does not only increase efficacy but also 
causes reduced harmful actions in target off-site. 
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